These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23494984)

  • 1. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients.
    Moltó J; Xinarianos G; Miranda C; Pushpakom S; Cedeño S; Clotet B; Owen A; Valle M
    Clin Pharmacokinet; 2013 Jul; 52(7):543-53. PubMed ID: 23494984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
    Arab-Alameddine M; Lubomirov R; Fayet-Mello A; Aouri M; Rotger M; Buclin T; Widmer N; Gatri M; Ledergerber B; Rentsch K; Cavassini M; Panchaud A; Guidi M; Telenti A; Décosterd LA; Csajka C;
    J Antimicrob Chemother; 2014 Sep; 69(9):2489-98. PubMed ID: 24821595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics.
    Calcagno A; Yilmaz A; Cusato J; Simiele M; Bertucci R; Siccardi M; Marinaro L; D'Avolio A; Di Perri G; Bonora S
    AIDS; 2012 Jul; 26(12):1529-33. PubMed ID: 22555164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults.
    Moltó J; Barbanoj MJ; Miranda C; Blanco A; Santos JR; Negredo E; Costa J; Domingo P; Clotet B; Valle M
    Clin Pharmacokinet; 2008; 47(10):681-92. PubMed ID: 18783298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients.
    Cattaneo D; Gervasoni C; Cozzi V; Baldelli S; Fucile S; Meraviglia P; Landonio S; Boreggio G; Rizzardini G; Clementi E
    Pharmacol Res; 2012 Feb; 65(2):198-203. PubMed ID: 21958880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of multiple-dose darunavir in combination with low-dose ritonavir in individuals with mild-to-moderate hepatic impairment.
    Sekar V; Spinosa-Guzman S; De Paepe E; Stevens T; Tomaka F; De Pauw M; Hoetelmans RM
    Clin Pharmacokinet; 2010 May; 49(5):343-50. PubMed ID: 20384396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.
    Zorrilla CD; Wright R; Osiyemi OO; Yasin S; Baugh B; Brown K; Coate B; Verboven P; Mrus J; Falcon R; Kakuda TN
    HIV Med; 2014 Jan; 15(1):50-6. PubMed ID: 23731450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin.
    Aquilante CL; Kiser JJ; Anderson PL; Christians U; Kosmiski LA; Daily EB; Hoffman KL; Hopley CW; Predhomme JA; Schniedewind B; Sidhom MS
    J Clin Pharmacol; 2012 Nov; 52(11):1725-38. PubMed ID: 22174437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
    Lê MP; Chaix ML; Chevret S; Bertrand J; Raffi F; Gallien S; El Abbassi EMB; Katlama C; Delobel P; Yazdanpanah Y; Saillard J; Molina JM; Peytavin G;
    J Antimicrob Chemother; 2018 Aug; 73(8):2120-2128. PubMed ID: 29905808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of darunavir/ritonavir in Asian HIV-1-infected children aged ≥7 years.
    Chokephaibulkit K; Prasitsuebsai W; Wittawatmongkol O; Gorowara M; Phongsamart W; Sophonphan J; Kerr SJ; Vanprapar N; Puthanakit T; Pasomsap C; Suwanlerk T; Sekar V; Burger D; Ananworanich J;
    Antivir Ther; 2012; 17(7):1263-9. PubMed ID: 22954687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.
    Kohlrausch FB; de Cássia Estrela R; Barroso PF; Suarez-Kurtz G
    Br J Clin Pharmacol; 2010 Jan; 69(1):95-8. PubMed ID: 20078617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients.
    Moltó J; Valle M; Miranda C; Cedeño S; Negredo E; Barbanoj MJ; Clotet B
    Antimicrob Agents Chemother; 2011 Jan; 55(1):326-30. PubMed ID: 21078942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients.
    Barrail-Tran A; Yazdanpanah Y; Goldwirt L; Chêne G; Colin C; Piketty C; Bollens D; Katlama C; Descamps D; Molina JM; Fagard C; Taburet AM;
    AIDS; 2010 Oct; 24(16):2581-3. PubMed ID: 20960678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.
    Kappelhoff BS; Huitema AD; Crommentuyn KM; Mulder JW; Meenhorst PL; van Gorp EC; Mairuhu AT; Beijnen JH
    Br J Clin Pharmacol; 2005 Feb; 59(2):174-82. PubMed ID: 15676039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
    Lubomirov R; di Iulio J; Fayet A; Colombo S; Martinez R; Marzolini C; Furrer H; Vernazza P; Calmy A; Cavassini M; Ledergerber B; Rentsch K; Descombes P; Buclin T; Decosterd LA; Csajka C; Telenti A;
    Pharmacogenet Genomics; 2010 Apr; 20(4):217-30. PubMed ID: 20139798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.
    Colbers A; Greupink R; Litjens C; Burger D; Russel FG
    Clin Pharmacokinet; 2016 Mar; 55(3):381-96. PubMed ID: 26369773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
    Boffito M; Miralles D; Hill A
    HIV Clin Trials; 2008; 9(6):418-27. PubMed ID: 19203907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.
    Cressey TR; Urien S; Hirt D; Halue G; Techapornroong M; Bowonwatanuwong C; Leenasirimakul P; Treluyer JM; Jourdain G; Lallemant M;
    Ther Drug Monit; 2011 Feb; 33(1):25-31. PubMed ID: 21233689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
    van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
    AIDS; 2000 Jun; 14(9):F103-10. PubMed ID: 10894270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.